Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05358106
Additional trial details provided through ANZCTR are available at the end of this record.
Registration number
NCT05358106
Ethics application status
Date submitted
23/03/2022
Date registered
3/05/2022
Date last updated
18/06/2023
Titles & IDs
Public title
Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.
Query!
Scientific title
A Phase 1, Single-blind, Partially Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of AntiBKV in Healthy Adult Volunteers.
Query!
Secondary ID [1]
0
0
MTx-AntiBKV-AU-1.02BKVI
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SAFE KIDNEY I
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
BK Virus Nephropathy
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - AntiBKV
Other interventions - Placebo
Active Comparator: AntiBKV neutralising antibody - AntiBKV infused i.v. over 30 minutes. Infusion parameters may be adjusted to bodyweight so that infusion rate does not exceed 60mg/kg per hour. AntiBKV will be administered as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2 (100, 500, 1000 or 2000 mg).
Placebo Comparator: Placebo - Solution containing no active excipients, infused i.v. over 30 minutes as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2.
Other interventions: AntiBKV
AntiBKV neutralising antibody
Other interventions: Placebo
Solution with no active ingredients
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Query!
Assessment method [1]
0
0
To assess the number of participants with treatment related adverse events following a single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Query!
Timepoint [1]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [2]
0
0
Change in blood haematology values
Query!
Assessment method [2]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Haematology data will be summarised for each scheduled visit, including observed values, change from baseline, number of out-of-range values and number of clinically significant values.
Query!
Timepoint [2]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [3]
0
0
Change in blood biochemistry values
Query!
Assessment method [3]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Biochemistry data will be summarised for each scheduled visit, including observed values, change from baseline, number of out-of-range values and number of clinically significant values.
Query!
Timepoint [3]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [4]
0
0
Change in urinalysis values
Query!
Assessment method [4]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Urinalysis data will be summarised for each scheduled visit, including observed values, change from baseline, number of out-of-range values and number of clinically significant values.
Query!
Timepoint [4]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [5]
0
0
Change in blood pressure
Query!
Assessment method [5]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Blood pressure results will be summarized for each scheduled timepoint, including observed values, change from baseline, number of out-of-range values and number of clinically significant values.
Query!
Timepoint [5]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [6]
0
0
Change in heart rate
Query!
Assessment method [6]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Heart rate will be summarized for each scheduled timepoint, including observed values, change from baseline, number of out-of-range values and number of clinically significant values.
Query!
Timepoint [6]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [7]
0
0
Change in respiratory rate
Query!
Assessment method [7]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Respiration rate will be summarized for each scheduled timepoint, including observed values, change from baseline, number of out-of-range values and number of clinically significant values.
Query!
Timepoint [7]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [8]
0
0
Change in body temperature
Query!
Assessment method [8]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Body temperature will be summarized for each scheduled timepoint, including observed values, change from baseline, number of out-of-range values and number of clinically significant values.
Query!
Timepoint [8]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [9]
0
0
Participants with abnormal physical examination findings.
Query!
Assessment method [9]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
Abnormal physical examination findings during scheduled physical exams will be listed.
Query!
Timepoint [9]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [10]
0
0
Change in P wave duration in electrocardiogram measurement
Query!
Assessment method [10]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
ECG parameters will be descriptively summarized for each scheduled timepoint, including observed values and change from baseline.
Query!
Timepoint [10]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [11]
0
0
Change in PR interval in electrocardiogram measurement
Query!
Assessment method [11]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
ECG parameters will be descriptively summarized for each scheduled timepoint, including observed values and change from baseline.
Query!
Timepoint [11]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Primary outcome [12]
0
0
Change in QRS duration in electrocardiogram measurement
Query!
Assessment method [12]
0
0
To evaluate the safety and tolerability of single ascending doses (Part 1) and multiple ascending doses (Part 2) of AntiBKV administered intravenously to healthy adult participants.
ECG parameters will be descriptively summarized for each scheduled timepoint, including observed values and change from baseline.
Query!
Timepoint [12]
0
0
Screening (Day -1) to final visit post-treatment (Day 113) for Part 1 and final visit post-treatment (Day 197) for Part 2.
Query!
Secondary outcome [1]
0
0
Pharmacokinetics measured by the maximum plasma concentration (Cmax)
Query!
Assessment method [1]
0
0
To assess the pharmacokinetic profile of AntiBKV in healthy participants after single (Part 1 and first dose in Part 2) or multiple (Part 2) intravenous dose administration.
Query!
Timepoint [1]
0
0
Treatment Day 1 to final visit (Day 113) for Part 1 and final visit (Day 197) for Part 2.
Query!
Secondary outcome [2]
0
0
Pharmacokinetics measured by the time of Cmax (Tmax)
Query!
Assessment method [2]
0
0
To assess the pharmacokinetic profile of AntiBKV in healthy participants after single (Part 1 and first dose in Part 2) or multiple (Part 2) intravenous dose administration.
Query!
Timepoint [2]
0
0
Treatment Day 1 to final visit (Day 113) for Part 1 and final visit (Day 197) for Part 2.
Query!
Secondary outcome [3]
0
0
Pharmacokinetics measured by the area under the curve (AUC)
Query!
Assessment method [3]
0
0
To assess the pharmacokinetic profile of AntiBKV in healthy participants after single (Part 1 and first dose in Part 2) or multiple (Part 2) intravenous dose administration.
Query!
Timepoint [3]
0
0
Treatment Day 1 to final visit (Day 113) for Part 1 and final visit (Day 197) for Part 2.
Query!
Secondary outcome [4]
0
0
Pharmacokinetics measured by the terminal elimination rate constant (?z)
Query!
Assessment method [4]
0
0
To assess the pharmacokinetic profile of AntiBKV in healthy participants after single (Part 1 and first dose in Part 2) or multiple (Part 2) intravenous dose administration.
Query!
Timepoint [4]
0
0
Treatment Day 1 to final visit (Day 113) for Part 1 and final visit (Day 197) for Part 2.
Query!
Secondary outcome [5]
0
0
Pharmacokinetics measured by the half life
Query!
Assessment method [5]
0
0
To assess the pharmacokinetic profile of AntiBKV in healthy participants after single (Part 1 and first dose in Part 2) or multiple (Part 2) intravenous dose administration.
Query!
Timepoint [5]
0
0
Treatment Day 1 to final visit (Day 113) for Part 1 and final visit (Day 197) for Part 2.
Query!
Secondary outcome [6]
0
0
Immunogenicity measured by anti-drug antibody (ADA) production
Query!
Assessment method [6]
0
0
Samples will be tested for the presence of ADAs. ADA titers and the presence of neutralizing antibodies will be determined for ADA positive samples
Query!
Timepoint [6]
0
0
Treatment Day 1 to final visit (Day 113) for Part 1 and final visit (Day 197) for Part 2.
Query!
Eligibility
Key inclusion criteria
1. Healthy male or female participants aged 18 years to 50 years at the time of consent
2. Ability to read, understand and provide written informed consent
3. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests, and other study procedures, including lifestyle restrictions for the duration
of the study
4. Healthy participants as established by medical history, laboratory examination,
physical examination, vital signs, and ECG during screening and as per the clinical
judgment of the investigator
5. Body mass index (BMI) of 18.0 to 32.0 kg/m2 (inclusive)
6. For Woman of Childbearing Potential (WOCBP): agrees to practice true abstinence or
agrees to use a highly effective method of contraception consistently from 30 days
prior to Day 1 until at least 30 days post-dose. Highly effective contraception
includes hormonal contraception, placement of intrauterine device (IUD) or
intrauterine system (IUS), or a vasectomized partner (performed at least 6 months
prior to her screening) who has been documented to no longer produce sperm. Verbal
confirmation from the participant through medical interview is acceptable. No
contraception requirements for participants in exclusive same-sex relationship.
7. For male participant: must agree to practice true abstinence or use condom if he has a
partner of childbearing potential or must be surgically sterilized (performed at least
6 months prior and documented to no longer produce sperm. Verbal confirmation through
medical interview is acceptable). Participant to practice abstinence (if applicable)
or use condom for at least 30 days post-dose. No contraception requirements for
participants in exclusive same-sex relationship.
8. Accessible veins in the forearms for venepuncture and/or intravenous cannulation
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
50
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Participant with active SARS-CoV-2 infection
2. Participants tested positive for human immunodeficiency virus (HIV antibody screen),
Hepatitis B virus (HBsAg screen) or Hepatitis C virus (HCV antibody screen)
3. History of administration of any investigational or non-registered drug within 30 days
or 5 half-lives, whichever is longer, prior to administration of study drug, or
planned administration during the course of study participation.
4. History of any reaction to monoclonal antibodies.
5. History of allergic disease or reactions likely to be exacerbated by any component of
the study drug, as assessed by the investigator, and/or known allergies to the trial
product or its components.
6. History of any major pulmonary, cardiovascular, renal, neurological (e.g.,
cerebrovascular events), metabolic, gastrointestinal, hepato-biliary, or hematological
functional abnormality, malignancy (except for adequately treated basal cell carcinoma
or squamous cell carcinoma of the skin), or clinically significant mental disability
that may interfere with the participant's ability to provide informed consent, as per
discretion of the investigator. Gilbert's syndrome and history of cholecystectomy or
cholecystitis will not be considered exclusionary.
7. Any abnormal laboratory finding at screening and at Day -1 (one retest is allowed at
screening and/or at Day -1) unless deemed not clinically significant and irrelevant
for study participation by the discretion of the investigator. Alanine
aminotransferase (ALT) and/or aspartate aminotransferase (AST) = 2 × upper limit of
normal and/or glomerular filtration rate (GFR) <60ml/min are always considered
exclusionary.
8. Acute illness (moderate or severe) and/or fever (body temperature = 38 °C) during the
72 hours prior to any planned study drug application.
9. Participants with altered immunocompetence such as participants with ongoing cancer
treatment, human immunodeficiency virus infection, organ transplant or any other
active immune system disorder. Participants with seasonal allergies and mild asthma
may be included.
10. Receipt of immunoglobulin or blood products within 6 months prior to enrolment.
11. Receipt of a monoclonal antibody within previous 6 months or 5 half-lives, whichever
is longer.
12. Planned surgery (excluding minor procedures such as tooth extraction or incision and
drainage) during the course of the study.
13. Receipt, or planned receipt of any standard vaccine within 7 days prior to and 7 days
post Day 1 or planned vaccination within 7 days prior to and post any subsequent
dosings.
14. History of alcoholism (>10 drinks/week) or drug addiction within 1 year prior to
screening.
15. Positive screen for drugs of abuse or alcohol (breath test) at screening or Day -1 and
prior to any subsequent dosings. A test may be repeated once at the discretion of the
investigator to confirm suspected false-positive results.
16. Use of prescription drugs within 7 days prior to Day 1 or for 5 half-lives whichever
is longer, or during the study, except for hormonal contraceptives.
17. Use of over-the-counter medication within 7 days prior to Day 1 or during the study;
medication such as paracetamol and ibuprofen may be permitted at the discretion of the
investigator and sponsor.
18. Receipt of immunosuppressive medications within 6 months prior to enrolment (receipt
of any course of systemic corticosteroids for more than a 7-day duration and with a
prednisolone equivalent dose of more than 5 mg per day within 6 months prior to
enrolment will exclude a participant; inhaled or topical steroids are allowed).
19. Pregnant, lactating, or planned pregnancy during the study period.
20. Inability to comply with the study protocol in the opinion of the investigator.
21. Participant has any plans to permanently relocate from the area prior to the
completion of the study or to leave for an extended period of time when study visits
would need to be scheduled.
22. Concurrent participation in another interventional clinical study investigating a
vaccine, drug, medical device, or medical procedure in the 30 days preceding the study
drug administration or during the course of the study.
23. Participant has clinically significant 12-lead ECG abnormalities at screening.
24. Abnormal vital signs including systolic blood pressure (SBP) < 90 or > 160 mmHg,
diastolic blood pressure (DBP) < 50 or > 95 mmHg, heart rate (HR) < 45 or > 100 bpm
(average of triplicate measurements) at screening.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/05/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/04/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
40
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
CMAX Clinical Research Pty Ltd - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Memo Therapeutics AG
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
BK virus (BKV) is a member of the polyomavirus family with a prevalence of up to 90% in the
general population. In immunocompromized individuals, such as kidney transplant recipients
(KTRs) who receive immunosuppressant therapy to prevent graft rejection, BKV turns into an
opportunistic pathogen. BK viremia has been reported to occur in 10-30% of KTRs. BKV is
recognized as a leading cause of impaired graft function and premature transplant loss, and
is therefore a serious condition in kidney transplant patients.
At present, there are no effective agents specifically against BKV available and thus no
standard treatment that can effectively reduce or prevent BKV infection/reactivation after
renal transplantation. Therefore, the proposed indication for the AntiBKV neutralizing
antibody is the treatment of BK virus infections and prevention of BK virus associated
complications in KTRs.
This study has been designed to evaluate the safety, tolerability, and pharmacokinetic of
ascending doses of AntiBKV, a fully human highly neutralising antibody against BKV,
administered as a single or multiple intravenous infusions to healthy adult participants. The
data obtained in this study will provide the basis for further clinical development of
AntiBKV.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05358106
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jürgen Beck
Query!
Address
0
0
Memo Therapeutics AG
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05358106
Additional trial details provided through ANZCTR
Accrual to date
Recruiting in Australia
Recruitment state(s)
SA
Recruitment hospital [1]
90
CMAX Clinical Research Pty Ltd
Recruitment postcode(s) [1]
94
5000
Funding & Sponsors
Funding source category [1]
76
Commercial sector/Industry
Name [1]
76
Memo Therapeutics AG
Address [1]
76
Wagistrasse 27 8952 Schlieren, Switzerland
Country [1]
76
Switzerland
Primary sponsor
Commercial sector/Industry
Primary sponsor name
Memo Therapeutics AG
Primary sponsor address
Wagistrasse 27
8952 Schlieren, Switzerland
Primary sponsor country
Switzerland
Secondary sponsor category [1]
75
Commercial sector/Industry
Name [1]
75
Accelagen Pty Ltd
Address [1]
75
Suite 2.02 785 Toorak Road, Hawthorn East Victoria, Australia 3123
Country [1]
75
Australia
Ethics approval
Ethics application status
Approved
Ethics committee name [1]
48
Bellberry Limited
Address [1]
48
123 Glen Osmond Rd, Eastwood SA 5063
Country [1]
48
Australia
Date submitted for ethics approval [1]
48
23/03/2022
Approval date [1]
48
27/04/2022
Ethics approval number [1]
48
Public notes
Contacts
Principal investigator
Title
333
0
Dr
Query!
Name
333
0
Jonathan Newchurch
Query!
Address
333
0
CMAX Clinical Research Pty Ltd
Query!
Country
333
0
Australia
Query!
Phone
333
0
0423223756
Query!
Fax
333
0
Query!
Email
333
0
[email protected]
Query!
Contact person for public queries
Title
334
0
Mr
Query!
Name
334
0
Greg Plunkett
Query!
Address
334
0
Suite 2.02 785 Toorak Road, Hawthorn East Victoria, Australia 3123
Query!
Country
334
0
Australia
Query!
Phone
334
0
+61 3 9114 2274
Query!
Fax
334
0
Query!
Email
334
0
[email protected]
Query!
Contact person for scientific queries
Title
335
0
Dr
Query!
Name
335
0
Jonathan Newchurch
Query!
Address
335
0
CMAX Clinical Research Pty Ltd
Query!
Country
335
0
Australia
Query!
Phone
335
0
0423223756
Query!
Fax
335
0
Query!
Email
335
0
[email protected]
Query!
Download to PDF